Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer.

ABSTRACT:

Background

Precise methods for postoperative risk stratification to guide the administration of adjuvant chemotherapy (ACT) in localized colorectal cancer (CRC) are still lacking. Here, we conducted a prospective, observational, and multicenter study to investigate the utility of circulating tumor DNA (ctDNA) in predicting the recurrence risk.

Methods

From September 2017 to March 2020, 276 patients with stage II/III CRC were prospectively recruited in this study and 240 evaluable patients were retained for analysis, of which 1290 serial plasma samples were collected. Somatic variants in both the primary tumor and plasma were detected via a targeted sequencing panel of 425 cancer-related genes. Patients were treated and followed up per standard of care.

Results

Preoper

SUBMITTER: Chen G 

PROVIDER: S-EPMC8130394 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature